Lonza completes HPAPI expansion

Lonza has completed an expansion at its API manufacturing site at Nansha, China, as part of its recent investment to expand mid-scale capacity there. This focused on extending the capabilities and capacity of development laboratories and kilo-scale cGMP manufacturing laboratories for clinical supply of HPAPIs.

The footprint has been expanded to 250 m² with additional analytical and manufacturing equipment. Operations are scheduled to begin this month and the company revealed that the first European and US-based customers have signed HPAPI programmes for the new laboratories.

“The expansion of our HPAPI capabilities at Nansha enables us to enter HPAPI manufacturing to meet growing global demand, especially in supporting clinical trials in oncology,” commented Jason Zhang, R&D director for small molecules. “Our presence in Nansha allows us to leverage world-class, high-quality and reliable local suppliers of raw materials, thus further increasing the speed of problem-solving and manufacturing.”